No Data
No Data
Huisheng Biotech (300871): Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals
Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals. The company achieved operating income of 1,020 billion yuan in 2023, -0.31% year-on-year, mainly due to downstream aquaculture losses and financial constraints
Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low
Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low utilization rate of new construction projects raises initial costs; 2) fixed increases send a positive signal, demonstrating the confidence of actual controllers in future development; 3) putting effort into R&D and innovation, and completing the production capacity layout for core raw materials. (Mainichi Keizai Shimbun)
Huisheng Biotech (300871.SZ) announced first-quarter results, changing profit to loss to RMB 16.4056 million
Huisheng Biotech (300871.SZ) released its report for the first quarter of 2024. The company's revenue was 2.07...
Express News | Huisheng Biotech: Net profit attributable to shareholders of listed companies in 2023 was 19.5 million yuan to 25 million yuan, down 52.57% to 63.00% from the same period last year.
Huisheng Biotech (300871.SZ): Net profit is expected to drop 52.57% to 63% year-on-year in 2023
On April 10, Gelonghui | Huisheng Biotech (300871.SZ) announced that it expects net profit of 19.5 million yuan to 25 million yuan in 2023, down 52.57% to 63% from the same period last year, after deducting non-net loss of 8.5 million yuan to 13 million yuan. In the early stages, the company did not accrue individual credit impairment losses on accounts receivable from individual customers based on a comprehensive assessment of factors such as customer repayment conditions, financial changes, and development trends in the pig breeding industry. Due to the company's recent acquisition of new information, the customer showed signs of business risk and intended to apply to the court for restructuring and pre-restructuring
Huisheng Biotech (300871) Company Review Report: The fixed increase plan highlights the company's confidence in development, the farming boom, and the company's priority benefits
Incident: On April 3, 2024, the company announced a plan to issue A shares to specific targets in 2024. The target of this fixed increase issuance is Chu Sheng Investment. The total amount of capital to be raised will not exceed RMB 250 million, after deducting the issuance fee
No Data